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Introduction: Hypertensive encephalopathy with the clinicoradiological entity posterior reversible encephalopathy
syndrome in the setting of venlafaxine as single therapy has not been reported earlier.
Case description: A 46-year-old man developed hypertensive encephalopathy associated with venlafaxine as single
therapy. Magnetic resonance imaging of the brain, pre and post gadolinium, carried out on day 2, displayed an
increased T2 signal in the cortex on both the T2 and FLAIR images throughout the frontal and temporal lobes and
in the cerebellum. Venlafaxine therapy was stopped. The patient gradually improved and he became seizure free
and the blood pressure successively became normal. A magnetic resonance imaging after six weeks displayed
marked regression of the abnormalities. On follow-up after 3 months, his blood pressure had been normal and he
had not had any symptoms. The prescribed antiepileptic drug was discontinued as well as antihypertensive
treatment. He had not experienced any new symptoms at follow-up after one year.
Discussion and evaluation: The patient in this report had hypertensive encephalopathy associated with
venlafaxine therapy. The imaging findings are compatible with hypertensive encephalopathy/posterior reversible
encephalopathy syndrome. Venlafaxine is a drug used very frequently. Venlafaxine may infrequently induce
hypertensive crisis.
Conclusion: Hypertensive encephalopathy may rarely occur in the setting of venlafaxine as single therapy even in
low to moderate doses. Patients on venlafaxine should have regular monitoring of blood pressure. Knowledge of
the side effects is vital. Venlafaxine must be discontinued if significant hypertension persists.
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Depression is usually associated with low systolic blood
pressure and less hypertension although medicines
intended for treatment of the same disorder can be as-
sociated with an increase in blood pressure. Some anti-
depressants are associated with both high diastolic and
systolic blood pressures and hypertension (Licht et al.
2009). Antidepressants are often used for long periods
and it is important to clarify any side effects of the
treatment. Venlafaxine is an antidepressant, belonging
to the serotonin-norepinephrine reuptake inhibitor class
of drugs, used for the therapy of depression and anxiety
disorders. It is also used (although not approved) as aCorrespondence: Bengt.Edvardsson@med.lu.se
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prophylaxis. The drug is usually well tolerated. Side ef-
fects include headache, dizziness, tremor, somnolence,
nausea and hypertension. Hypertensive encephalopathy
with the clinicoradiological entity posterior reversible
encephalopathy syndrome (PRES) in the setting of ven-
lafaxine as single therapy has not been reported earlier.
I here describe a 46-year-old man who developed hy-
pertensive encephalopathy associated with venlafaxine
as single therapy.Case description
A 46-year-old man presented with generalized seizures.
He was on venlafaxine therapy for depression and anxiety
disorder. He had taken venlafaxine for sex weeks. He
started on 75 mg/day which was increased to 150 mg/dayn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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in that dose. Blood pressure was monitored and he was all
the time normotensive. There was no history of seizures,
hypertension or other diseases. He had no other medica-
tions. The seizures were followed by nausea, vomiting, se-
vere headache, visual disturbances and confusion. He also
experienced severe shortness of breath and began to
cough up frothy pink sputum. On presentation in the
emergency department, he was sleepy, had a pulse of 135
beats/min, a blood pressure of 231/133 mm Hg, and a re-
spiratory rate of 35-38. His chest X-ray indicated pulmon-
ary oedema. He was treated for acute congestive heart
failure due to severe hypertension. The hypertension was
treated with labetalol and enalaprilat intravenously. Venla-
faxine therapy was stopped. Complete blood picture, and
blood biochemistry were normal. On day 2 of admittance
he experienced further seizures. Treatment with phenytoin
and levetiracetam intravenously proved to be effective and
the seizures stopped. An electroencephalogram showed
diffuse slowing indicating an encephalopathy. Cerebro-
spinal examination was normal. Echocardiography was
normal. Magnetic resonance imaging (MRI) of the brain,
pre and post gadolinium, carried out on day 2, displayed
an increased T2 signal in the cortex on both the T2 and
FLAIR images throughout the frontal and temporal lobes
and in the cerebellum consistent with hypertensive en-
cephalopathy/PRES (Figure 1 a and b). No contrast en-
hancement was seen and diffusion weighted imaging
showed no signs of ischemia. The mental status changes
improved after treatment. Oral anticonvulsive and antihy-
pertensive treatment continued. Other secondary causes
of hypertension were excluded. The patient gradually im-
proved and he became seizure free and the blood pressure
successively became normal. Physical examination showedFigure 1 Primary MRI T2 and FLAIR images a and b displaying an inc
lobes and in the cerebellum consistent with hypertensive encephalopno signs of heart disease. Repeated chest X-ray was nor-
mal. The patient was discharged to his home on day 12. A
MRI after six weeks displayed marked regression of the
abnormalities (Figure 2 a and b). The patient was seen
again after three months. The prescribed antiepileptic
drug was discontinued as well as antihypertensive treat-
ment. His blood pressure had been normal and he had not
had any seizures. He denied any cardiac symptoms. He
had not experienced any new symptoms at follow-up after
one year. He is recurrently evaluated by psychiatrist. He
now uses a different medicine for his depression and anx-
iety disorder.
Discussion
The case study highlights a patient with hypertensive en-
cephalopathy in the setting of venlafaxine as single ther-
apy. The patient had no earlier known hypertension and
he recovered completely after discontinuation of venla-
faxine. Consequently, venlafaxine was the only rational
cause of the hypertensive encephalopathy in this case.
Hypertension is a known side effect of venlafaxine ther-
apy. However, the incidence of venlafaxine induced high
blood pressure is low and the effect on blood pressure is
weak (Lacy et al. 2003). (Thase 1998) found in a study of
venlafaxine diastolic blood pressure elevations only in
4,8% of patients. The mean rise was only 1, 02 mmHg.
Hypertensive crisis was not observed. (Fabre & Putman
1987) observed a rise in systolic blood pressure after ad-
ministration of a125 to 250 mg dose of venlafaxine in
healthy volunteers. In a study with venlafaxine, (Schweizer
et al. 1991) found an elevation of diastolic blood pressure
of 5, 6 mmHg versus baseline. (Chugh et al. 2013) ob-
served in a study of venlafaxine and fluoxetine a signifi-
cant rise in blood pressure which was in line with earlierreased signal in the cortex throughout the frontal and temporal
athy/PRES.
Figure 2 MRI after 6 weeks a and b displaying marked regression of the abnormalities.
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of blood pressure is dose dependent, happening more
often at higher doses (Thase 1998). The half-life of venla-
faxine is relatively short, which explains the generally rapid
normalization of blood pressure after discontinuation of
venlafaxine (Lacy et al. 2003). The mechanism behind ven-
lafaxine induced hypertension is unclear. The hyperten-
sion may be caused by noradrenergic potentiation by
venlafaxine (Sawynok et al. 2001). To my knowledge, ven-
lafaxine induced acute hypertension is earlier only re-
ported in two case reports. (Pardal et al. 2001) reported a
case of high blood pressure associated with venlafaxine.
The dose of venlafaxine was 150 mg/day and blood pres-
sure was 162/110 mm Hg. However, no signs of hyperten-
sive emergency/encephalopathy were noticed. Venlafaxine
was stopped and the patient became normotensive. In an-
other study (Khurana & Baudendistel 2003) described a
case with hypertensive crisis associated with venlafaxine.
Blood pressure was 224/148 mm Hg. The dose of venla-
faxine was only 75 mg/day but that patient also took
disulfiram which may have increased the toxicity of venla-
faxine. Disulfiram as single therapy can also cause hyper-
tension (Khurana & Baudendistel 2003). A MRI of the
brain displayed abnormalities consistent with hypertensive
encephalopathy/PRES. After blood pressure treatment and
discontinuing of venlafaxine the patient improved and be-
came normotensive and discharged on day 3.
However, it must be emphasized that the risk of hyper-
tensive crisis during treatment with venlafaxine is low.
Venlafaxine is a drug used very frequently. Only two
case reports in the literature describing hypertensive cri-
ses during medication of venlafaxine have been pub-
lished. Thus, the evidence is weak. Hypertensive crisis
could also be a confounding factor. Additional reportsare needed to strengthen the association between venla-
faxine and hypertensive crisis.
Conclusions
Hypertensive encephalopathy may rarely occur in the set-
ting of venlafaxine as single therapy even in low to moder-
ate doses. Patients on venlafaxine should have regular
monitoring of blood pressure. Knowledge of the side ef-
fects is vital. Venlafaxine must be discontinued if signifi-
cant hypertension persists.
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